Why it matters now
The pharmaceutical industry is under increasing pressure to accelerate drug development and demonstrate value beyond traditional clinical trials. Real-world evidence (RWE) offers a promising avenue to achieve this, by leveraging data from routine clinical practice. However, the acceptance criteria for RWE vary significantly across different regulatory bodies worldwide. Understanding these nuances is critical for companies seeking efficient and successful product registrations, as it directly impacts development timelines and resource allocation in a competitive environment.
Who is exposed
Pharmaceutical companies face direct impacts on their drug development timelines, regulatory submission costs, and market access strategies. Regulatory agencies are exposed to evolving frameworks and the need to balance innovation with patient safety. Contract research organizations must adapt their service offerings to support RWE generation and analysis, impacting their operational models and client relationships.
Most relevant for: Head of Regulatory Affairs, R&D Director, Chief Medical Officer
What this Viewpoint covers
- Which major regulatory bodies have published guidance on RWE for approvals?
- How do acceptance criteria for RWE differ across key geographical regions?
- What types of RWE are most commonly accepted for specific therapeutic areas?
- Which regulatory precedents exist for RWE-supported drug approvals?
- How are post-market surveillance requirements integrating RWE?
Signals to watch
- New regulatory guidance documents or draft policies on RWE.
- Pilot programs or initiatives by regulatory bodies involving RWE.
- Presentations or publications from regulatory officials on RWE acceptance.
- Collaborations between regulators and industry on RWE frameworks.
Decisions it supports
- Designing global regulatory submission strategies incorporating RWE.
- Prioritizing RWE generation efforts for specific markets or products.
- Allocating resources for RWE infrastructure and expertise.
How it is built
Prepared after your order from dated public sources - such as pharma & biotech filings and announcements, regulatory records, trials, patents and trade data, where relevant - and our market model. Reported facts are cited, estimates are labelled and our assessment is marked as such, following our research method. You receive our verdict, the evidence, who is exposed, the signals to watch and recommended actions, within 24 hours.
Questions
What is real-world evidence (RWE)?
Real-world evidence (RWE) is clinical evidence derived from real-world data (RWD) regarding the usage and potential benefits or risks of a medical product. RWD can come from sources like electronic health records, claims data, product registries, and patient-generated data, reflecting routine clinical practice.
Why is regulatory acceptance of RWE a current challenge?
While RWE offers significant potential, its varied nature and the lack of standardized methodologies for its generation and analysis pose challenges for regulators. Each agency is developing its own approach to ensure data quality, relevance, and reliability for decision-making, leading to diverse acceptance criteria.
Does this Viewpoint provide a definitive list of accepted RWE types?
This Viewpoint analyzes current regulatory guidance and precedents to identify trends in RWE acceptance across different jurisdictions and therapeutic areas. It highlights the types of RWE that have gained traction, without providing an exhaustive or static list, as policies are continuously evolving.